Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.
Muhammad Haisum MaqsoodBrittany N WeberRebecca H HabermanKristen I Lo SiccoSripal BangaloreMichael S GarshickPublished in: ACR open rheumatology (2022)
JAK inhibitors when compared with active comparator arms increased the risk of VTE, which was dependent on duration of exposure. Future clinical trials with extended follow-up are needed to clarify the safety profiles of JAK inhibitors.